1. Home
  2. CRSP vs SRAD Comparison

CRSP vs SRAD Comparison

Compare CRSP & SRAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

N/A

Current Price

$46.38

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Logo Sportradar Group AG

SRAD

Sportradar Group AG

N/A

Current Price

$19.24

Market Cap

5.0B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
CRSP
SRAD
Founded
2013
2001
Country
Switzerland
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
5.0B
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
CRSP
SRAD
Price
$46.38
$19.24
Analyst Decision
Buy
Strong Buy
Analyst Count
17
17
Target Price
$70.29
$30.18
AVG Volume (30 Days)
2.0M
2.3M
Earning Date
05-05-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$289,590,000.00
N/A
Revenue This Year
$1,082.59
$24.03
Revenue Next Year
$87.74
$15.00
P/E Ratio
N/A
$49.48
Revenue Growth
9169.85
N/A
52 Week Low
$30.06
$15.73
52 Week High
$78.48
$32.22

Technical Indicators

Market Signals
Indicator
CRSP
SRAD
Relative Strength Index (RSI) 38.40 55.16
Support Level N/A $17.68
Resistance Level $60.63 $19.67
Average True Range (ATR) 2.30 0.89
MACD -0.84 0.14
Stochastic Oscillator 10.22 60.82

Price Performance

Historical Comparison
CRSP
SRAD

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About SRAD Sportradar Group AG

Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.

Share on Social Networks: